Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$1.90M$1.90M+24.0% vs Q2 2018 Net Income-$1.41M-$1.41MN/M vs Q2 2018 EPS Diluted-$0.02-$0.02N/M vs Q2 2018 Gross Profit$765,000+44.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,114,000N/M Free Cash Flowderived-$1,225,000N/M Margins · derivedGross margin40.2%+5.6 pt vs Q2 2018
Operating margin-75.1%+20.5 pt vs Q2 2018
Net margin-74.3%+21.0 pt vs Q2 2018
ended Dec 31, 2018 · filed Feb 13, 2019 · 44 d after period end